Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05741866
Other study ID # 2022/HE001952
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 3, 2023
Est. completion date December 2023

Study information

Verified date November 2022
Source The University of Queensland
Contact ProP - Project Manager
Phone +61 (0) 7 36467671
Email catherine.obrien2@health.qld.gov.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare a chlorhexidine impregnated dressing for peripheral intravenous catheters (PIVCs) to the standard dressing currently used in general medical and surgical inpatient wards. The main questions it aims to answer are: - Study Feasibility - Occurrence of infectious complications related to the PIVC Participants will be randomly allocated to receive either of the below dressings to cover and secure their PIVC: - The standard dressing used at their hospital, or - The intervention dressing which has Chlorhexidine gluconate (CHG) on it Researchers will compare standard and CHG dressings to see if the presence of CHG improves the occurrence of infectious complications related to the PIVC.


Description:

This study is a multi-centre, two-arm, parallel group adaptive Randomized Controlled Trial (RCT) to test effectiveness, cost-effectiveness, and safety of 3M™ Tegaderm™ Antimicrobial IV Advanced Securement dressings with standard polyurethane dressings for PIVCs. The study has two phases. Phase I is an internal feasibility pilot for which only feasibility outcomes will be considered (no analysis). At this time (n=300) an independent Data Safety Monitoring Committee (DSMC) comprised of a biostatistician, physician and expert trialist will review pre-defined blinded analyses of feasibility and safety data. Phase II will then go ahead if feasibility outcomes are satisfactory, and will involve continuation of trial recruitment to complete a definitive RCT. If Phase II does not proceed then all outcomes will be reported at the end of Phase I. Setting and sample: Australia: The ProP Trial will be undertaken in the general medical/surgical and oncology/hematology departments at the Queensland Children's Hospital (QCH; Site 1), and the general medical/surgical departments at the Royal Brisbane and Women's Hospital (RBWH; Site 2) Brisbane, Australia. These are both large quaternary referral teaching hospitals (Site 1: 359 beds; Site 2: 929 beds). France: The ProP Trial will be undertaken in the University Hospital of Poitiers (PUH), a large referral teaching hospital with 959 acute beds. Patients will be recruited at the Emergency Department, before being admitted to medical wards. Sample size: Phase 1: The investigators will recruit 300 patients (200 Australia and 100 France) with 150 patients per arm. This sample size is not determined by statistical power but to test protocol feasibility and gain estimates of effect to inform a sample size calculation for a full trial. The investigators aim to recruit 300 patients over 16 weeks (19 per week). Phase 2: The investigators will continue recruitment to the sample size recommended by the DSMC and the Trial Steering Committee. The investigators anticipate this will be no more than a sample of 2624 patients (1312/group) which would have 90% power to detect an absolute 5% reduction in the primary outcome from 22% to 17% (2-way alpha 0.05) (http://powerandsamplesize.com/calculators).


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 2023
Est. primary completion date November 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years and older
Eligibility Inclusion Criteria: - PIVC to be inserted with expected dwell >48 hours - Provided written and informed consent (patient or carer) Australia only • =6 years of age (due to size of dressing) France only • =18 years of age Exclusion Criteria: - Burned, non-intact or scarred skin at the insertion site - Known allergy to CHG or transparent dressing adhesives - Palliative care patients on end-of-life pathway - Patient who has already participated in the study - Placement of a PIVC in an emergency, that does not allow the usual rules of hygiene for insertion to be adhered to. Additional exclusions to Australian study only - Non-English-speaking patients without interpreter - Under the care of Child and Family Services and unable to gain consent from case worker (paediatric patients) Additional exclusions to French study only - Patients not benefiting from the French Social Security scheme or not benefiting from it through a third party, - Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection. - Known pregnant or breastfeeding women - Predictably difficult vascular access (IV drug addiction, obesity)

Study Design


Intervention

Device:
Chlorhexidine gluconate impregnated bordered polyurethane dressing
PIVCs will be dressed and secured at the participating sites RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing. QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.
Standard bordered polyurethane dressing
PIVCs will be dressed and secured as per standard practice at the participating sites RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing. QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.

Locations

Country Name City State
Australia Royal Brisbane and Women's Hospital Herston Queensland
Australia Queensland Children's Hospital South Brisbane Queensland
France University Hospital of Poitiers Poitiers Nouvelle-Aquitaine

Sponsors (5)

Lead Sponsor Collaborator
The University of Queensland Griffith University, Queensland Children's Hospital, Royal Brisbane and Women's Hospital, University Hospital of Poitiers

Countries where clinical trial is conducted

Australia,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility for a definitive RCT The feasibility of conducting a definitive RCT will be assessed against the following criteria:
i. Study Eligibility as per inclusion/exclusion criteria (=80% of screened participants will be eligible for study inclusion) ii. Participant Recruitment onto study (=80% of eligible participants will provide informed consent to participate in the study) iii. Retention of study participants (<10% will be lost to follow up) iv. Protocol fidelity of study participants (=80% will receive the allocated intervention) v. Missing data for primary outcome 2 (<5% of primary outcome 2 data will be unable to be collected) vi. Satisfaction of participants/parents and staff (<10% report "low" satisfaction with the intervention arm (rated low/medium/high) vii. An estimate of catheter-related infectious complications (defined as per primary outcome 2) in the control group that indicate a fully powered multi-site RCT is achievable
On completion of 300 participants
Primary Catheter-related infectious complications and phlebitis Proportion of patients with a composite measure of PIVC Colonization; PIVC local infection; PIVC-associated Bloodstream Infection (BSI) and Phlebitis. These measures are defined below in secondary outcomes.
If patients meet more than one of the following [e.g., phlebitis and PIVC local infection], both will be collected however only counted once for the composite measure.
Daily until 48hours after study PIVC is removed.
Secondary PIVC tip colonization >15 cfu of a pathogen semi-quantitative method, or =1000 cfu of a pathogen per mL broth method.
PIVC tips will be collected based on Nurse and laboratory availability at time of PIVC removal.
Daily until 48hours after study PIVC is removed.
Secondary PIVC local infection without Bloodstream Infection (BSI) Proportion of patients with a PIVC local infection without BSI as defined by NHSN 2021 criteria for Cardiovascular System VASC-Arterial or Venous Infection (CVS-VASC); adult and child/infant criteria.
Collected daily by either the research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
Daily until 48hours after study PIVC is removed.
Secondary PIVC-associated Bloodstream Infection Proportion of patients with a laboratory Confirmed Bloodstream Infection, as defined by NHSN 2021 adult and infant criteria
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
Daily until 48hours after study PIVC is removed.
Secondary Phlebitis Either pain or tenderness [>1 on a scale of 0 to 10]), or at least 2 of erythema, swelling, purulence or palpable cord.
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Daily until 48hours after study PIVC is removed.
Secondary PIVC device failure Proportion of patients, a composite of infiltration/ extravasation, blockage/occlusion (with/without leakage), phlebitis (as defined above), thrombosis, dislodgement (complete/partial) or infection (as defined above).
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Daily until 48hours after study PIVC is removed.
Secondary Dressing durability Proportion of patients with dressing durability assessed as:
(i) the dressing remains adhered to the skin on all four sides until PIVC removal; and, (ii) accidental dislodgement (excluding patients who deliberately remove their PIVC).
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Daily until study PIVC is removed.
Secondary Skin colonization Reported semi-quantitatively as scant, 1+, 2+, 3.
PIVC skin swabs will be collected based on Nurse and laboratory availability at time of PIVC removal.
On study PIVC removal
Secondary Adverse skin event Proportion of patients with skin complications at PIVC site: mechanical (e.g. pressure injury, skin tears, blisters, bruising) or inflammatory complications (e.g. contact/allergic dermatitis, skin rash, pruritus).
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Daily until 48hours after study PIVC is removed.
Secondary Serious adverse event Proportion of patients with anaphylactic reaction to CHG in dressing; or mortality related to PIVC infection.
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record.
Daily until 48hours after study PIVC is removed.
Secondary Cost effectiveness Direct and indirect healthcare costs to the health system, including cost per complication avoided.
Collected daily by either research nurse or medical investigators from either direct observation, consultation with the clinical staff or review of the medical record and microbiology results.
A random subset of 15% of participants will have all subsequent devices recorded until completion of treatment for the participant's current admission. Date of discharge will be recorded for all participants to calculate length of stay.
Until discharge.
Secondary Patient reported experience measures of the dressing Proportion of participants/parents who report their satisfaction with the dressing rated low/medium/high with respective prompts of:
"I'd rather use a different dressing next time"
"The dressing was ok, but I'm happy to try other types"
"It was a really good dressing and I'd like to use this one again"
A Patient-Reported Experience Measure survey will be conducted on study PIVC removal.
Patient's will have the opportunity to comment on the dressing and their satisfaction with it at any time during study participation.
Daily until 48hours after study PIVC is removed.
Secondary Clinician reported experience measures of the dressing including application and removal Proportion of clinicians who report their satisfaction with the dressing rated low/medium/high with respective prompts of:
"I'd rather use a different dressing next time"
"The dressing was ok, but I'm happy to try other types"
"It was a really good dressing and I'd like to use this one again"
Collected opportunistically between dressing application to 48 hours after study PIVC removal.
Daily until 48hours after study PIVC is removed.
See also
  Status Clinical Trial Phase
Recruiting NCT02905955 - Vacuumtherapy After Venous Hybrid Procedures Phase 4
Not yet recruiting NCT02868372 - Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine N/A
Enrolling by invitation NCT02559453 - Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds N/A
Completed NCT02744144 - Wound Bacterial Microbiota and Their Antibiotic Resistance N/A
Active, not recruiting NCT01939145 - Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation Phase 4
Completed NCT00998907 - PDS*Plus and Wound Infections After Laparotomy N/A
Completed NCT01141335 - Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair Phase 4
Terminated NCT00654641 - Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy N/A
Completed NCT00576745 - A Comparison Of The 3M TM S Surgical Skin Closure System To The Standard Vicryl Suture Closure of Sternotomy Incisions During Cardiac Surgery Phase 1
Completed NCT00402727 - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection Phase 3
Recruiting NCT00150852 - Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus. Phase 2
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT04596124 - Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze N/A
Active, not recruiting NCT04584957 - Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.) N/A
Recruiting NCT03960970 - Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries Phase 2
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Completed NCT02018094 - The Amputation Surgical Site Infection Trial (ASSIT) Phase 4
Terminated NCT03269968 - Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery N/A
Enrolling by invitation NCT02945761 - High Concentration of Sugar Solution Irrigation Promotes the Healing of Infected Wound N/A
Not yet recruiting NCT02882360 - Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum Phase 4